Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma

Clinical Cancer Research

Volumn 13, Issue 8, 2007, Pages 2504-2511

  Soussain, Carole ^a   Muldoon, Leslie L ^a,b   Varallyay, Csanad ^a   Jahnke, Kristoph ^a   DePaula, Luciana ^b   Neuwelf, Edward A ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GADOLINIUM; METHOTREXATE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BRAIN VENTRICLE TUMOR; CELL INFILTRATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG MEGADOSE; GLIOSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IRRADIATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SUBARACHNOID SPACE; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOMA, B-CELL; MAGNETIC RESONANCE IMAGING; RATS; RATS, NUDE; TRANSPLANTATION, HETEROLOGOUS; WHOLE-BODY IRRADIATION;

EID: 34247868144     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2379     Document Type: Article

References (37)

1. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002;95: 1504-10.
2. Rubenstein JL, Treseler P, O'Brien JM. Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am 2005;19:705-17.
3. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006;24:1281-8.
4. Grant JW, Isaacson PG. Primary central nervous system lymphoma. Brain Pathol 1992;2:97-109.
5. Schwechheimer K, Braus DF, Schwarzkopf G, Feller AC, Volk B, Muller-Hermelink HK. Polymorphous high-grade B cell lymphoma is the predominant type of spontaneous primary cerebral malignant lymphomas. Histological and immunomorphological evaluation of computed tomography-guided stereotactic brain biopsies. Am J Surg Pathol 1994;18:931-7.
6. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034-43.
7. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643-8.
8. Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 1999;43:241-7.
9. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580-90.
10. Shah GD, DeAngelis LM. Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005;19:611-27.
11. Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery 2001;48:1033-40.
12. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004;54:131-40.
13. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006;24:4570-4.
14. Assaf N, Hasson T, Hoch-Marchaim H, et al. An experimental model for infiltration of malignant lymphoma to the eye and brain. Virchows Arch 1997;431: 459-67.
15. Schabet M, Herrlinger U. Animal models of leptomeningeal metastasis. J Neurooncol 1998;38: 199-205.
16. Zubair AC, Ali SA, Rees RC, Goepel JR, Winfield DA, Goyns MH. Analysis of the colonization of unirradiated and irradiated SCID mice by human lymphoma and non-malignant lymphoid cells. Leuk Lymphoma 1996;22:463-71.
17. Saini M, Bellinzona M, Weichhold W, Samii M. A new xenograft model of primary central nervous system lymphoma. J Neurooncol 1999;43:153-60.
18. Remsen LG, McCormick CI, Sexton G, Pearse HD, Garcia R, Neuwelt EA. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence. Clin Cancer Res 1995;1: 731-9.
19. Hughes JA, Weckert HA, van Holst Pellekaan C, Benson EM, Dunn IS. Translocations into human chromosome 14 JH region: factors influencing downstream abortive immunoglobulin class switching. Mol Immunol 2003;40:573-83.
20. Lin CH, Kuo KT, Chuang SS, et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 2006;12:1152-6.
21. Kambara H, Saeki Y, Chiocca EA. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res 2005;65:11255-8.
22. Roman-Goldstein SM, Goldman DL, Howieson J, Belkin R, Neuwelt EA. MR of primary CNS lymphoma in immunologically normal patients. AJNR Am J Neuroradiol 1992;13:1207-13.
23. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21:1044-9.
24. Blay JY, Bouhour D, Carrie C, et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 1995;86:2922-9.
25. Herrlinger U, Kuker W, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005;57: 843-7.
26. Omuro AM, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 2005;64:69-74.
27. Dukic SF, Heurtaux T, Kaltenbach ML, Hoizey G, Laliemand A, Vistelle R. Influence of schedule of administration on methotrexate penetration in brain tumours. Eur J Cancer 2000;36:1578-84.
28. Neuwelt EA, Barnett P, McCormick CI, Remsen LG, Kroll RA, Sexton G. Differential permeability of a human brain tumor xenograft in the nude rat: the impact of tumor size and method of administration on optimizing delivery of biologically diverse agents. Clin Cancer Res 1998;4:1549-56.
29. DeAngelis LM. Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan. Ann Neurol 1993;33:308-11.
30. Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology 2002; 59:1557-62.
31. Cha S, Johnson G, Wadghiri YZ, et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 2003;49:848-55.
32. Johnson G, Wetzel SG, Cha S, Babb J, Tofts PS. Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 2004;51:961-8.
33. Hall DE, Moffat BA, Stojanovska J, et al. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res 2004;10:7852-9.
34. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006;8:259-67.
35. Fisher MJ, Khademian ZP, Simon EM, Zimmerman RA, Bilaniuk LT. Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. AJNR Am J Neuroradiol 2005;26:1686-9.
36. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901-3.
37. + B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004;103:4429-31.